STUDY OBJECTIVE: To implement and assess a community-based pharmaceutical care program for patients with asthma. DESIGN: Prospective, randomized, controlled trial. SETTING:Community pharmacies (11 control, 11 intervention) in Malta. PATIENTS: Community-dwelling patients with asthma. INTERVENTIONS: A comprehensive asthma education and monitoring program was implemented. Intervention patients received verbal counseling, an educational video, an information leaflet, and subsequent monitoring with reinforcement; control patients received routine dispensing services. MEASUREMENTS AND MAIN RESULTS: Parameters assessed at baseline and at 4, 8, and 12 months were health-related quality of life, peak expiratory flow (PEF), inhaler technique, compliance with therapy, hospitalization rates, days lost from work, asthma symptoms, and patient satisfaction. Health-related quality of life of the intervention patients improved at 12 months (p=0.044). In the same time period, PEF significantly decreased in control patients compared with intervention patients (p=0.009) whereas inhaler technique improved in the intervention group (p=0.021). There were significantly fewer self-reported hospitalizations in intervention patients. CONCLUSIONS: A community-based pharmaceutical care program was appreciated by the participants and had a positive impact on the vitality of patients with asthma, inhaler technique, and PEE.
RCT Entities:
STUDY OBJECTIVE: To implement and assess a community-based pharmaceutical care program for patients with asthma. DESIGN: Prospective, randomized, controlled trial. SETTING: Community pharmacies (11 control, 11 intervention) in Malta. PATIENTS: Community-dwelling patients with asthma. INTERVENTIONS: A comprehensive asthma education and monitoring program was implemented. Intervention patients received verbal counseling, an educational video, an information leaflet, and subsequent monitoring with reinforcement; control patients received routine dispensing services. MEASUREMENTS AND MAIN RESULTS: Parameters assessed at baseline and at 4, 8, and 12 months were health-related quality of life, peak expiratory flow (PEF), inhaler technique, compliance with therapy, hospitalization rates, days lost from work, asthma symptoms, and patient satisfaction. Health-related quality of life of the intervention patients improved at 12 months (p=0.044). In the same time period, PEF significantly decreased in control patients compared with intervention patients (p=0.009) whereas inhaler technique improved in the intervention group (p=0.021). There were significantly fewer self-reported hospitalizations in intervention patients. CONCLUSIONS: A community-based pharmaceutical care program was appreciated by the participants and had a positive impact on the vitality of patients with asthma, inhaler technique, and PEE.
Authors: Ada G G Stuurman-Bieze; Mirjam E A P Kokenberg; Hilde Tobi; Willem O de Boer; Jasperien E van Doormaal; Lolkje T W Jong-van den de Berg; Th F J Tromp Journal: Pharm World Sci Date: 2005-10
Authors: Sandra R Wilson; Cynthia S Rand; Michael D Cabana; Michael B Foggs; Jill S Halterman; Lynn Olson; William M Vollmer; Rosalind J Wright; Virginia Taggart Journal: J Allergy Clin Immunol Date: 2012-03 Impact factor: 10.793